Review: Drug-eluting stents for coronary artery disease do not reduce mortality more than bare-metal stentsPDF
ACP J Club. 2007 May-Jun;146:66. doi:10.7326/ACPJC-2007-146-3-066
Related Content in the Archives
• Drug-eluting stents increased risk for late cardiac death or myocardial infarction more than bare-metal stents
Clinical Impact Ratings
Nordmann AJ, Briel M, Bucher HC.Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis.Eur Heart J. 2006; 27:2784-814. [PubMed ID: 17020889]
In patients with coronary artery disease who are receiving percutaneous coronary intervention and stent placement, are drug-eluting stents (DESs) more effective than bare-metal stents (BMSs) in reducing mortality?
Data sources: MEDLINE, EMBASE/Excerpta Medica, Web of Science, and the Cochrane Library (to April 2006); UpToDate (version 2005); Clinical Evidence Concise (2004, issue 12); Web sites; experts in the field; and reference lists.
Study selection and assessment: Randomized controlled trials (RCTs) that compared DESs (using sirolimus or paclitaxel) with BMSs in patients with coronary artery disease and reported mortality after a follow-up of ≥ 1 year. Trials involving stents in nonnative coronary arteries were excluded. 17 RCTs (n = 8221) (mean age range 56 to 67 y, 56% to 89% men) met the selection criteria: 8 RCTs (n = 3032) using sirolimus DESs and 10 RCTs (n = 5470) using paclitaxel DESs (1 RCT used both). Antiplatelet therapy with clopidogrel, ticlopidine, or cilostazol was recommended in all trials for ≥ 2 to 6 months after stent placement in addition to aspirin indefinitely. Quality assessment included allocation concealment, blinding, and follow-up.
Outcomes: Total, cardiac, and noncardiac mortality and stent thrombosis.
DESs and BMSs did not differ for total mortality or cardiac mortality at any follow-up interval (Table). Treatment effect for these outcomes did not differ between trials using sirolimus or paclitaxel DESs. At 2 years, noncardiac mortality was increased with DESs more than with BMSs (Table); this increase was observed in 5 RCTs using sirolimus DESs (odds ratio [OR] 2.7, 95% CI 1.2 to 6.1) but not in 7 RCTs using paclitaxel DESs (OR 1.2, CI 0.6 to 2.5). Groups did not differ for noncardiac mortality at other follow-up intervals (Table). Groups did not differ for early (≤ 30 d) or late (> 30 d) stent thrombosis (Table).
In patients with coronary artery disease, drug-eluting stents are not more effective in reducing mortality than bare-metal stents up to 4 years after implantation. Drug-eluting stents, especially those with sirolimus, may increase the risk for noncardiac mortality after the first year.
Sources of funding: Santésuisse and Gottfried Bangerter-Rhyner-Foundation.
For correspondence: Dr. A.J. Nordmann, University Hospital Basel, Basel, Switzerland. E-mail firstname.lastname@example.org.
Table. Drug-eluting stents vs bare-metal stents in coronary artery disease at 1 to 4 years*
|Outcomes||Follow-up||Number of trials (n)||Odds ratio (95% CI)|
|Total mortality||1 y||17 (8221)||0.9 (0.7 to 1.3)|
|2 y||12 (4631)||1.1 (0.8 to 1.6)|
|3 y||9 (4105)||1.3 (0.9 to 1.7)|
|4 y||2 (1293)||1.5 (0.9 to 2.3)|
|Cardiac mortality||1 y||17 (8221)||0.8 (0.5 to 1.4)|
|2 y||12 (4631)||0.7 (0.4 to 1.2)|
|3 y||9 (4105)||1.0 (0.6 to 1.6)|
|4 y||2 (1293)||1.2 (0.6 to 2.4)|
|Noncardiac mortality||1 y||17 (8221)||1.1 (0.6 to 1.8)|
|2 y||12 (4631)||1.7 (1.01 to 2.9)|
|3 y||9 (4105)||1.5 (0.9 to 2.3)|
|4 y||2 (1293)||1.7 (0.9 to 3.1)|
|Stent thrombosis||≤ 30 d||17 (8221)||1.2 (0.6 to 2.1)|
|> 30 d||16 (7395)||1.3 (0.7 to 2.6)|
*CI defined in Glossary.
DESs have dramatically decreased the need for coronary artery bypass graft (CABG) surgery and repeated PCI. However, late stent thrombosis is a small but important risk with DESs because it is commonly associated with sudden death or acute MI.
The clinical occurrence of stent thrombosis after stent implantation can be defined as acute (< 24 h), subacute (1 to 30 d), late (30 d to 1 y), or very late (> 1 y). The clinical diagnosis of stent thrombosis can be defined as “definite” if proven angiographically or pathologically, “probable” if an MI occurs in the distribution of the stented artery, or “possible” if death is unexplained (1). Risk for subacute stent thrombosis is about 1% for both DESs and BMSs, but risk for very late stent thrombosis continues for at least 4 years with DESs at a rate of 2 to 4 events/1000 patients per year (1−3). The presumed cause is delayed or incomplete endothelialization of the stent struts. The unanswered question is whether the decrease in risk for death and MI from avoiding CABG, restenosis, or repeated PCI is greater than the risk for death or MI from late stent thrombosis.
Pfisterer and colleagues compared the incidence of late clinical events among patients assigned to either a DES or a BMS. The study suggested an early reduction in death or MI from less TVR with DESs but a late increase in death or MI from stent thrombosis after discontinuation of clopidogrel therapy. The meta-analysis by Nordmann and colleagues, as well as several subsequent reports that have been used to support current DES labeling (1−3), showed no long-term increase in death or MI rates with 3 to 6 months of dual antiplatelet therapy. Therefore, the small increase in risk for stent thrombosis with DES implantation does not outweigh its benefit compared with BMS implantation. However, ambiguity remains regarding the role of off-label DES implantation in complicated patients (e.g., those with diabetes, acute MI, or multivessel coronary disease) and for patients with complex coronary lesions (e.g., those with longer length, smaller diameter, bifurcations, or vein grafts) in which risk for late stent thrombosis is increased. Furthermore, because there has been no controlled clinical trial examining DESs in these complicated circumstances, no comparative data exist regarding risk for death or MI with such alternative treatments as CABG or BMS.
Although premature discontinuation of dual antiplatelet therapy (< 3 to 6 mo) is a risk factor for stent thrombosis and many cases of stent thrombosis occur despite therapy, the optimal duration of antiplatelet therapy is unknown. No data exist showing the benefit of prolonged dual antiplatelet therapy after 6 months, but 12 months of therapy after DES implantation has been recommended recently, if the bleeding risk is low (4, 5). Similarly, no data exist to support indefinite dual antiplatelet therapy, an impractical general strategy given the cost and attendant risk for bleeding. Consequently, DESs should be avoided in the presence of financial barriers to continuing prolonged dual antiplatelet therapy, social barriers that may limit patient compliance, or medical issues involving bleeding risks or the need for invasive or surgical procedures in the following year that would interrupt antiplatelet therapy.
Patients should understand the benefits and risks of all treatment options and be able to commit to uninterrupted dual antiplatelet therapy for 1 year before DES implantation can be recommended. Interventionalists should thoughtfully select patients for a DES and use optimal implantation techniques. Unfortunately, industry-funded observational registry studies are not likely to clarify the issue of long-term DES safety, and the lack of randomized trials in complicated patients with complex coronary lesions further precludes evidence-based comparisons between DES and BMS, CABG, and medical therapy. The solution will probably come from newer stent iterations with antithrombotic coatings, bioabsorbable polymers, or biodegradable struts.
Eric R. Bates, MD
University of Michigan
Ann Arbor, Michigan, USA
1. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-9. [PubMed ID: 17296821]
2. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119:1056-61. [PubMed ID: 17145250]
3. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008. [PubMed ID: 17296824]
4. Hodgson JM, Stone GW, Michael Lincoff A, et al. Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-Eluting Stent Task Force. Catheter Cardiovasc Interv. 2007;69:327-33. [PubMed ID: 17219373]
5. Grines CL, Bonow RO, Casey DE Jr., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol. 2007;49:734-9. [PubMed ID: 17291948]